Brind.
  1. FDA granted regulatory milestones to Medtronic, which is integrating with Abbott's Instinct sensor.
  2. Medtronic plans to integrate with Abbott’s Libre sensors as both firms develop multi-analyte sensor technology.

Abbott Japan announces investments in new manufacturing and R&D facilities, coinciding with the availability of over-the-counter Continuous Glucose Monitoring (CGM).

1 report, 0 independent Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Abbott Japan announces investments in new manufacturing and R&D facilities, coinciding with the availability of over-the-counter Continuous Glucose Monitoring (CGM).

Who's involved

What this event is mainly about
Abbott JapanTexas

Keep exploring

Part of

Medtronic plans to integrate with Abbott’s Libre sensors as both firms develop multi-analyte sensor technology. All 1 developments

Within FDA granted regulatory milestones to Medtronic, which is integrating with Abbott's Instinct sensor.

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet